Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Trial Profile

A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary) ; Solifenacin
  • Indications Overactive bladder; Urinary incontinence
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 21 May 2018 Results of a post-hoc analysis of pooled placebo-controlled trials (NCT00910845, NCT00910520, NCT01767519 and NCT01945489) assessing the risk of Clean Intermittent Catheterization, presented at the 113th Annual Meeting of the American Urological Association
    • 01 Feb 2017 Results of post-hoc analysis published in the Journal of Urology.
    • 10 May 2016 Primary endpoint of percentage of patients with 100% reduction in incontinence episodes in treatment cycle 1 has been met, according to results presented at the 111th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top